FDA Approves Jazz Pharmaceuticals' Ziihera for Advanced HER2-Positive Gastroesophageal Cancer

The FDA has granted approval for two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) to treat adults with unresectable, locally advanced, or metastatic HER2-positive gastroesophageal adenocarcinoma. This decision follows positive Phase III trial results, showing improved progression-free and overall survival, offering a new treatment option for patients with this aggressive cancer.